> Detailanzeige

Gröschel, Stefan; Schlenk, Richard F.; Engelmann, Jan; Rockova, Veronika; Teleanu, Veronica; Kühn, Michael W.M.; Eiwen, Karina; Erpelinck, Claudia; Havermans, Marije; Lübbert, Michael; Germing, Ulrich; Schmidt-Wolf, Ingo G.H.; Beverloo, H. Berna; Schuurhuis, Gerrit J.; Ossenkoppele, Gert J.; Schlegelberger, Brigitte; Verdonck, Leo F.; Vellenga, Edo; Verhoef, Gregor; Vandenberghe, Peter; Pabst, Thomas; Bargetzi, Mario; Krauter, Jürgen; Ganser, Arnold; [...]

Deregulated Expression ofEVI1Defines a Poor Prognostic Subset ofMLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Deregulated Expression ofEVI1Defines a Poor Prognostic Subset ofMLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
  • Beteiligte: Gröschel, Stefan; Schlenk, Richard F.; Engelmann, Jan; Rockova, Veronika; Teleanu, Veronica; Kühn, Michael W.M.; Eiwen, Karina; Erpelinck, Claudia; Havermans, Marije; Lübbert, Michael; Germing, Ulrich; Schmidt-Wolf, Ingo G.H.; Beverloo, H. Berna; Schuurhuis, Gerrit J.; Ossenkoppele, Gert J.; Schlegelberger, Brigitte; Verdonck, Leo F.; Vellenga, Edo; Verhoef, Gregor; Vandenberghe, Peter; Pabst, Thomas; Bargetzi, Mario; Krauter, Jürgen; Ganser, Arnold; [...]
  • Erschienen: American Society of Clinical Oncology (ASCO), 2013
  • Erschienen in: Journal of Clinical Oncology, 31 (2013) 1, Seite 95-103
  • Sprache: Englisch
  • DOI: 10.1200/jco.2011.41.5505
  • ISSN: 0732-183X; 1527-7755
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: PurposeTo evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements.Patients and MethodsWe identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis.ResultsWe divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1+) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1+was the sole prognostic factor, predicting for inferior overall survival (OS; hazard ratio [HR], 2.06; P = .003), relapse-free survival (HR, 2.28; P = .002), and event-free survival (HR, 1.79; P = .009). EVI1+AMLs with t(11q23) in first complete remission (CR) had a significantly better outcome after allogeneic transplantation compared with other consolidation therapies (5-year OS, 54.7% v 0%; Mantel-Byar, P = .0006). EVI1−t(9;11) AMLs had lower WBC counts, more commonly FAB M5 morphology, and frequently had additional trisomy 8 (39.6%; P < .001). Among t(9;11) AMLs, EVI1+again was the sole independent adverse prognostic factor for survival.ConclusionDeregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1+MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR.
  • Zugangsstatus: Freier Zugang